CA
TEVA icon

CoreCap Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

CoreCap Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-67
Closed -$2.27K – 3342
2026
Q2 		$2.27K Buy
67
+10
+18% +$333 ﹤0.01% 2508
2026
Q1 		$1.72K Sell
57
-500
-90% -$16.1K ﹤0.01% 2445
2025
Q4 		$17.4K Buy
557
+513
+1,166% +$12.6K ﹤0.01% 1735
2025
Q3 		$889 Hold
44
– – ﹤0.01% 2500
2025
Q2 		$737 Hold
44
– – ﹤0.01% 2462
2025
Q1 		$676 Hold
44
– – ﹤0.01% 2609
2024
Q4 		$970 Sell
44
-1,000
-96% -$18.2K ﹤0.01% 2380
2024
Q3 		$18.8K Buy
+1,044
New +$18.3K ﹤0.01% 1588
2024
Q2 		– Sell
-1,044
Closed -$14.7K – 2474
2024
Q1 		$14.7K Buy
+1,044
New +$13.2K ﹤0.01% 1605
2022
Q4 		$1.82K Buy
+200
New +$1.75K ﹤0.01% 1953
2022
Q1 		– Sell
-71
Closed -$1K – 1926
2021
Q4 		$1K Buy
+71
New +$641 ﹤0.01% 2251

Other funds holding TEVA

WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CAM
Cacti Asset Management Atlanta, Georgia $1.89B AUM 58.55% 1-Year Est. Return
IRC
Investors Research Corp Atlanta, Georgia $569M AUM 15.41% 1-Year Est. Return
VEM
Vann Equity Management Plano, Texas $168M AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $179M AUM 29.67% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

CoreCap Advisors's TEVA Position: Q3 2026 in Review

CoreCap Advisors sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2026, closing a stake of 67 shares — an estimated $2.27K sold.

CoreCap Advisors first reported a position in TEVA in Q4 2021 and held it in 11 quarters. The position peaked at $18.8K in Q3 2024. 10 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

  • CoreCap Advisors reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2026 after selling out during the quarter.
  • CoreCap Advisors sold 67 Teva Pharmaceutical Industries Limited shares in Q3 2026, an estimated $2.27K.
  • CoreCap Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q4 2021 and held it in 11 quarters.
  • CoreCap Advisors's Teva Pharmaceutical Industries Limited position peaked at $18.8K in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.